Karyopharm Therapeutics (KPTI) Revenue (2012 - 2026)
Karyopharm Therapeutics (KPTI) revenue from Sep 30, 2012 to Mar 31, 2026. The TTM Karyopharm Therapeutics (KPTI) revenue is $151M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Karyopharm Therapeutics (KPTI) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +6.33% |
| 3 Years TTM | +0.67% |
| 5 Years TTM | +5.95% |
| 10 Years TTM | +88.99% |
| All Time TTM | +62.13% |
Annual Revenue change of Karyopharm Therapeutics (KPTI)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $35M | -75.99% |
| 2025 | $146M | +0.57% |
| 2024 | $145M | -0.54% |
| 2023 | $146M | -7.03% |
| 2022 | $157M | -25.14% |
| 2021 | $210M | +94.12% |
| 2020 | $108M | +164.34% |
| 2019 | $41M | +34.77% |
| 2018 | $30M | +1784.47% |
| 2017 | $1.61M | +973.33% |
| 2016 | $150K | -40.00% |
| 2015 | $250K | +8.70% |
| 2014 | $230K | -41.03% |
| 2013 | $390K | -38.10% |
| 2012 | $630K | +320.00% |
| 2011 | $150K | N/A |
| 2010 | $0 | N/A |
| 2009 | $0 | N/A |
Comparison Karyopharm Therapeutics (KPTI) five years revenue CAGR with competitors
Karyopharm Therapeutics (KPTI) five years revenue CAGR is 5.95%.